MDA Awards $500,000 Grant to Accelerate ALS Research Through the HEALEY ALS Platform Trial at Massachusetts General Hospital
September 19, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) is proud to announce a new clinical research grant of $500,000 over three years, awarded to Sabrina Paganoni,...
Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
September 04, 2024 03:00 ET
|
Actimed Therapeutics
London, UK – 4th September 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and...
Fitness World Canada Partners with Augie’s Quest in the Mission to Cure ALS
September 03, 2024 11:03 ET
|
Fitness World
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- This September, Fitness World Canada joins forces with Augie’s Quest, an organization dedicated to finding a cure for ALS (Amyotrophic...
DiamiR Biosciences Secures EU Patent Covering the Use of microRNA Biomarkers from Bodily Fluids for Differential Diagnosis of Amyotrophic Lateral Sclerosis
August 01, 2024 08:02 ET
|
DiamiR
NEW HAVEN, CT, and MONMOUTH JUNCTION, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that...
PathMaker Neurosystems Announces $2.16 Million Award from U.S. Department of Defense for ALS Clinical Trial
June 05, 2024 06:00 ET
|
PathMaker Neurosystems Inc.
PathMaker Neurosystems receives $2.16 million award from United States Department of Defense for an expanded ALS clinical trial of its MyoRegulator device
Amyotrophic Lateral Sclerosis Market On Track For USD 1,271.6 Mn Revenue By 2033, Growing At 6.5% CAGR | Dimension Market Research
May 28, 2024 11:21 ET
|
Dimension Market Research
New York, May 28, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Amyotrophic Lateral Sclerosis Market size was valued at USD 673.4 million in 2023 and is further anticipated to reach USD...
Muscular Dystrophy Association’s Impact to End ALS Continues with Fourth Annual Lou Gehrig Day at Major League Baseball Games
May 21, 2024 09:07 ET
|
Muscular Dystrophy Association
New York, May 21, 2024 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) is gathering its extended community at Major League Baseball (MLB) parks across the United States, uniting ALS...
Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answering the Call’
April 29, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, April 29, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced programming and fundraising events in support of people living with Amyotrophic Lateral...
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
March 12, 2024 15:10 ET
|
Spherix Global Insights
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming...
AB Science annonce que Santé Canada a émis un Avis de Non-Conformité-Retrait (ANC-R) pour le masitinib dans la SLA
February 26, 2024 12:32 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE SANTÉ CANADA A ÉMIS UN AVIS DE NON-CONFORMITÉ-RETRAIT (ANC-R) POUR LE MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE AB SCIENCE A L'INTENTION DE...